Control of pathogenicity and disease specificity of a T-lymphomagenic gammaretrovirus by E-box motifs but not by an overlapping glucocorticoid response element

Journal of Virology

Volumn 83, Issue 1, 2009, Pages 336-346

  Ejegod, Ditte ^a   Sørensen, Karina Dalsgaard ^a   Mossbrugger, Ilona ^b   Quintanilla Martinez, Leticia ^b   Schmidt, Jörg ^b   Pedersen, Finn Skou ^a  

^a AARHUS UNIVERSITY   (Denmark)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; TRANSCRIPTION FACTOR RUNX; VIRUS DNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DNA RESPONSIVE ELEMENT; E BOX ELEMENT; ENHANCER REGION; LATENT PERIOD; MOUSE; MUTANT; MYELOID LEUKEMIA; NONHUMAN; PATHOGENICITY; PHENOTYPE; PRIORITY JOURNAL; REGENERATION; RETROVIRUS; T CELL LYMPHOMA; T LYMPHOCYTE; WILD TYPE; ANIMAL; GENETICS; INCIDENCE; LYMPHOMA; MUTATION; PSYCHOSEXUAL DEVELOPMENT; VIROLOGY;

GAMMARETROVIRUS; MURINAE;

ANIMALS; DNA, VIRAL; GAMMARETROVIRUS; INCIDENCE; LATENCY PERIOD (PSYCHOLOGY); LYMPHOMA; MICE; MUTATION; RESPONSE ELEMENTS;

EID: 58149396888     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.01368-08     Document Type: Article

References (60)

1. Bain, G., I. Engel, E. C. Robanus Maandag, H. P. te Riele, J. R. Voland, L. L. Sharp, J. Chun, B. Huey, D. Pinkel, and C. Murre. 1997. E2A deficiency leads to abnormalities in αβ T-cell development and to rapid development of T-cell lymphomas. Mol. Cell. Biol. 17:4782-4791.
2. Bain, G., S. Gruenwald, and C. Murre. 1993. E2A and E2-2 are subunits of B-cell-specific E2-box DNA-binding proteins. Mol. Cell. Biol. 13:3522-3529.
3. Bain, G., and C. Murre. 1998. The role of E-proteins in B- and T-lymphocyte development. Semin. Immunol. 10:143-153.
4. Bain, G., M. W. Quong, R. S. Soloff, S. M. Hedrick, and C. Murre. 1999. Thymocyte maturation is regulated by the activity of the helix-loop-helix protein, E47. J. Exp. Med. 190:1605-1616.
5. Bhadra, S., M. M. Lozano, and J. P. Dudley. 2005. Conversion of mouse mammary tumor virus to a lymphomagenic virus. J. Virol. 79:12592-12596.
6. Bruland, T., H. Y. Dai, L. A. Lavik, L. I. Kristiansen, and A. Dalen. 2001. Gender-related differences in susceptibility, early virus dissemination and immunosuppression in mice infected with Friend murine leukaemia virus variant FIS-2. J. Gen. Virol. 82:1821-1827.
7. Bruland, T., L. A. Lavik, H. Y. Dai, and A. Dalen. 2003. A glucocorticoid response element in the LTR U3 region of Friend murine leukaemia virus variant FIS-2 enhances virus production in vitro and is a major determinant for sex differences in susceptibility to FIS-2 infection in vivo. J. Gen. Virol. 84:907-916.
8. Bruland, T., L. A. Lavik, H. Y. Dai, and A. Dalen. 2003. Identification of Friend murine retrovirus-infected immune cells and studies of the effects of sex and steroid hormones in the early phase of infection. APMIS 111:878-890.
9. Bundy, L. M., M. Ru, B. F. Zheng, L. Cheng, P. K. Pattengale, J. L. Portis, and H. Fan. 1995. Biological characterization and molecular cloning of murine C-type retroviruses derived from the TSZ complex from mainland China. Virology 212:367-382.
10. Celander, D., and W. A. Haseltine. 1987. Glucocorticoid regulation of murine leukemia virus transcription elements is specified by determinants within the viral enhancer region. J. Virol. 61:269-275.
11. Celander, D., B. L. Hsu, and W. A. Haseltine. 1988. Regulatory elements within the murine leukemia virus enhancer regions mediate glucocorticoid responsiveness. J. Virol. 62:1314-1322.
12. Chatis, P. A., C. A. Holland, J. W. Hartley, W. P. Rowe, and N. Hopkins. 1983. Role for the 3′ end of the genome in determining disease specificity of Friend and Moloney murine leukemia viruses. Proc. Natl. Acad. Sci. USA 80:4408-4411.
13. Chatis, P. A., C. A. Holland, J. E. Silver, T. N. Frederickson, N. Hopkins, and J. W. Hartley. 1984. A 3′ end fragment encompassing the transcriptional enhancers of nondefective Friend virus confers erythroleukemogenicity on Moloney leukemia virus. J. Virol. 52:248-254.
14. Corneliussen, B., A. Thornell, B. Hallberg, and T. Grundstrom. 1991. Helix-loop-helix transcriptional activators bind to a sequence in glucocorticoid response elements of retrovirus enhancers. J. Virol. 65:6084-6093.
15. DesGroseillers, L., and P. Jolicoeur. 1984. The tandem direct repeats within the long terminal repeat of murine leukemia viruses are the primary determinant of their leukemogenic potential. J. Virol. 52:945-952.
16. Engel, I., C. Johns, G. Bain, R. R. Rivera, and C. Murre. 2001. Early thymocyte development is regulated by modulation of E2A protein activity. J. Exp. Med. 194:733-745.
17. Engel, I., and C. Murre. 2004. E2A proteins enforce a proliferation checkpoint in developing thymocytes. EMBO J. 23:202-211.
18. Engel, I., and C. Murre. 1999. Ectopic expression of E47 or E12 promotes the death of E2A-deficient lymphomas. Proc. Natl. Acad. Sci. USA 96:996-1001.
19. Ethelberg, S., B. Hallberg, J. Lovmand, J. Schmidt, A. Luz, T. Grundstrom, and F. S. Pedersen. 1997. Second-site proviral enhancer alterations in lymphomas induced by enhancer mutants of SL3-3 murine leukemia virus: negative effect of nuclear factor 1 binding site. J. Virol. 71:1196-1206.
20. Ethelberg, S., J. Lovmand, J. Schmidt, A. Luz, and F. S. Pedersen. 1997. Increased lymphomagenicity and restored disease specificity of AML1 site (core) mutant SL3-3 murine leukemia virus by a second-site enhancer variant evolved in vivo. J. Virol. 71:7273-7280.
21. Ethelberg, S., A. B. Sorensen, J. Schmidt, A. Luz, and F. S. Pedersen. 1997. An SL3-3 murine leukemia virus enhancer variant more pathogenic than the wild type obtained by assisted molecular evolution in vivo. J. Virol. 71:9796-9799.
22. Ethelberg, S., B. D. Tzschaschel, A. Luz, S. J. Diaz-Cano, F. S. Pedersen, and J. Schmidt. 1999. Increased induction of osteopetrosis, but unaltered lymphomagenicity, by murine leukemia virus SL3-3 after mutation of a nuclear factor 1 site in the enhancer. J. Virol. 73:10406-10415.
23. Fleming, T. J., M. L. Fleming, and T. R. Malek. 1993. Selective expression of Ly-6G on myeloid lineage cells in mouse bone marrow. RB6-8C5 mAb to granulocyte-differentiation antigen (Gr-1) detects members of the Ly-6 family. J. Immunol. 151:2399-2408.
24. Fredrickson, T. N., W. Y. Langdon, P. M. Hoffman, J. W. Hartley, and H. C. Morse III. 1984. Histologic and cell surface antigen studies of hematopoietic tumors induced by Cas-Br-M murine leukemia virus. J. Natl. Cancer Inst. 72:447-454.
25. Glud, S. Z., A. B. Sorensen, M. Andrulis, B. Wang, E. Kondo, R. Jessen, L. Krenacs, E. Stelkovics, M. Wabl, E. Serfling, A. Palmetshofer, and F. S. Pedersen. 2005. A tumor-suppressor function for NFATc3 in T-cell lymphomagenesis by murine leukemia virus. Blood 106:3546-3552.
26. Goldrath, A. W., and M. J. Bevan. 1999. Selecting and maintaining a diverse T-cell repertoire. Nature 402:255-262.
27. Golemis, E. A., N. A. Speck, and N. Hopkins. 1990. Alignment of U3 region sequences of mammalian type C viruses: identification of highly conserved motifs and implications for enhancer design. J. Virol. 64:534-542.
28. Granger, S. W., L. M. Bundy, and H. Fan. 1999. Tandemization of a subregion of the enhancer sequences from SRS 19-6 murine leukemia virus associated with T-lymphoid but not other leukemias. J. Virol. 73:7175-7184.
29. Hallberg, B., and T. Grundstrom. 1988. Tissue specific sequence motifs in the enhancer of the leukaemogenic mouse retrovirus SL3-3. Nucleic Acids Res. 16:5927-5944.
30. Hallberg, B., J. Schmidt, A. Luz, F. S. Pedersen, and T. Grundstrom. 1991. SL3-3 enhancer factor 1 transcriptional activators are required for tumor formation by SL3-3 murine leukemia virus. J. Virol. 65:4177-4181.
31. Hardy, R. R., C. E. Carmack, S. A. Shinton, J. D. Kemp, and K. Hayakawa. 1991. Resolution and characterization of pro-B and pre-pro-B cell stages in normal mouse bone marrow. J. Exp. Med. 173:1213-1225.
32. Hays, E. F., and G. Bristol. 1992. Observations on lymphomagenesis and lymphoma in AKR mice. A description of prelymphoma changes in the thymus and phenotypic diversity of lymphomas induced by SL3-3 virus. Thymus 19:219-234.
33. Hays, E. F., G. C. Bristol, S. McDougall, J. L. Klotz, and M. Kronenberg. 1989. Development of lymphoma in the thymus of AKR mice treated with the lymphomagenic virus SL 3-3. Cancer Res. 49:4225-4230.
34. Hestdal, K., F. W. Ruscetti, J. N. Ihle, S. E. Jacobsen, C. M. Dubois, W. C. Kopp, D. L. Longo, and J. R. Keller. 1991. Characterization and regulation of RB6-8C5 antigen expression on murine bone marrow cells. J. Immunol. 147:22-28.
35. Jones, S. 2004. An overview of the basic helix-loop-helix proteins. Genome Biol. 5:226.
36. Kina, T., K. Ikuta, E. Takayama, K. Wada, A. S. Majumdar, I. L. Weissman, and Y. Katsura. 2000. The monoclonal antibody TER-119 recognizes a molecule associated with glycophorin A and specifically marks the late stages of murine erythroid lineage. Br. J. Haematol. 109:280-287.
37. Koch, W., W. Zimmermann, A. Oliff, and R. Friedrich. 1984. Molecular analysis of the envelope gene and long terminal repeat of Friend mink cell focus-inducing virus: implications for the functions of these sequences. J. Virol. 49:828-840.
38. Lagasse, E., and I. L. Weissman. 1996. Flow cytometric identification of murine neutrophils and monocytes. J. Immunol. Methods 197:139-150.
39. Leib-Mosch, C., J. Schmidt, M. Etzerodt, F. S. Pedersen, R. Hehlmann, and V. Erfle. 1986. Oncogenic retrovirus from spontaneous murine osteomas. II. Molecular cloning and genomic characterization. Virology 150:96-105.
40. Lenz, J., D. Celander, R. L. Crowther, R. Patarca, D. W. Perkins, and W. A. Haseltine. 1984. Determination of the leukaemogenicity of a murine retrovirus by sequences within the long terminal repeat. Nature 308:467-470.
41. Lenz, J., R. Crowther, S. Klimenko, and W. Haseltine. 1982. Molecular cloning of a highly leukemogenic, ecotropic retrovirus from an AKR mouse. J. Virol. 43:943-951.
42. Lewis, A. F., T. Stacy, W. R. Green, L. Taddesse-Heath, J. W. Hartley, and N. A. Speck. 1999. Core-binding factor influences the disease specificity of Moloney murine leukemia virus. J. Virol. 73:5535-5547.
43. Lovmand, J., A. B. Sorensen, J. Schmidt, M. Ostergaard, A. Luz, and F. S. Pedersen. 1998. B-cell lymphoma induction by Akv murine leukemia viruses harboring one or both copies of the tandem repeat in the U3 enhancer. J. Virol. 72:5745-5756.
44. Martiney, M. J., L. S. Levy, and J. Lenz. 1999. Suppressor mutations within the core binding factor (CBF/AML1) binding site of a T-cell lymphomagenic retrovirus. J. Virol. 73:2143-2152.
45. Martiney, M. J., K. Rulli, R. Beaty, L. S. Levy, and J. Lenz. 1999. Selection of reversions and suppressors of a mutation in the CBF binding site of a lymphomagenic retrovirus. J. Virol. 73:7599-7606.
46. Massari, M. E., and C. Murre. 2000. Helix-loop-helix proteins: regulators of transcription in eucaryotic organisms. Mol. Cell. Biol. 20:429-440.
47. Mertz, J. A., F. Mustafa, S. Meyers, and J. P. Dudley. 2001. Type B leukemogenic virus has a T-cell-specific enhancer that binds AML-1. J. Virol. 75:2174-2184.
48. Morrison, H. L., B. Soni, and J. Lenz. 1995. Long terminal repeat enhancer core sequences in proviruses adjacent to c-myc in T-cell lymphomas induced by a murine retrovirus. J. Virol. 69:446-455.
49. Nielsen, A. L., P. L. Norby, F. S. Pedersen, and P. Jorgensen. 1996. Various modes of basic helix-loop-helix protein-mediated regulation of murine leukemia virus transcription in lymphoid cell lines. J. Virol. 70:5893-5901.
50. Nielsen, A. L., N. Pallisgaard, F. S. Pedersen, and P. Jorgensen. 1994. Basic helix-loop-helix proteins in murine type C retrovirus transcriptional regulation. J. Virol. 68:5638-5647.
51. Nieves, A., L. S. Levy, and J. Lenz. 1997. Importance of a c-Myb binding site for lymphomagenesis by the retrovirus SL3-3. J. Virol. 71:1213-1219.
52. Nilsson, P., B. Hallberg, A. Thornell, and T. Grundstrom. 1989. Mutant analysis of protein interactions with a nuclear factor I binding site in the SL3-3 virus enhancer. Nucleic Acids Res. 17:4061-4075.
53. Ringold, G. M., K. R. Yamamoto, G. M. Tomkins, M. Bishop, and H. E. Varmus. 1975. Dexamethasone-mediated induction of mouse mammary tumor virus RNA: a system for studying glucocorticoid action. Cell 6:299-305.
54. Schmidt, J., A. Luz, and V. Erfle. 1988. Endogenous murine leukemia viruses: frequency of radiation-activation and novel pathogenic effects of viral isolates. Leuk. Res. 12:393-403.
55. Shinnick, T. M., R. A. Lerner, and J. G. Sutcliffe. 1981. Nucleotide sequence of Moloney murine leukaemia virus. Nature 293:543-548.
56. Sørensen, K. D., S. Kunder, L. Quintanilla-Martinez, J. Sorensen, J. Schmidt, and F. S. Pedersen. 2007. Enhancer mutations of Akv murine leukemia virus inhibit the induction of mature B-cell lymphomas and shift disease specificity towards the more differentiated plasma cell stage. Virology 362:179-191.
57. Sørensen, K. D., L. Quintanilla-Martinez, S. Kunder, J. Schmidt, and F. S. Pedersen. 2004. Mutation of all Runx (AML1/core) sites in the enhancer of T-lymphomagenic SL3-3 murine leukemia virus unmasks a significant potential for myeloid leukemia induction and favors enhancer evolution toward induction of other disease patterns. J. Virol. 78:13216-13231.
58. Speck, N. A., B. Renjifo, E. Golemis, T. N. Fredrickson, J. W. Hartley, and N. Hopkins. 1990. Mutation of the core or adjacent LVb elements of the Moloney murine leukemia virus enhancer alters disease specificity. Genes Dev. 4:233-242.
59. Zaiman, A. L., and J. Lenz. 1996. Transcriptional activation of a retrovirus enhancer by CBF (AML1) requires a second factor: evidence for cooperativity with c-Myb. J. Virol. 70:5618-5629.
60. Zaiman, A. L., A. Nieves, and J. Lenz. 1998. CBF, Myb, and Ets binding sites are important for activity of the core I element of the murine retrovirus SL3-3 in T lymphocytes. J. Virol. 72:3129-3137.